Drug intelligence / Profile preview

D565 + D930

Development stage: Unknown

Overview

Combination of two investigational agents, D565 and D930. D565 and D930 have been studied together in pharmacokinetic and pharmacodynamic evaluations, but detailed information regarding their mechanism of action, therapeutic class, or primary indication is not publicly available. Both agents appear to be experimental pharmaceuticals as referenced in pediatric corticosteroid regimen and pharmacokinetic studies[1].

Beyond the preview

Go deeper on D565 + D930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D565 + D930.

Explore the full profile